ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
Conference call on Monday, June 25th at 2:30 pm CET/8:30 am EDT
- Focuses development efforts on solid tumor indications
- Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer.
- Expands eryaspase production capacity in the United States and France
- Plans to cease development in acute lymphoblastic leukemia (ALL), including withdrawal of European Marketing Authorization Application (MAA)
LYON, France and CAMBRIDGE Mass., June 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications. The company also announced that it plans to cease its development program for eryaspase in acute lymphoblastic leukemia (ALL), including the withdrawal of its previously submitted MAA for eryaspase for the treatment of relapsed and refractory ALL.
In 2017, ERYTECH announced positive results from a Phase 2b clinical trial of eryaspase combined with chemotherapy in patients suffering from second-line metastatic pancreatic cancer, as well as the intended launch of a pivotal Phase 3 clinical trial in this indication. Set-up activities are on track and the Phase 3 trial is expected to begin enrollment in the third quarter of 2018. ERYTECH now confirms that it intends to sponsor a Phase 2 proof-of-concept clinical trial of eryaspase later this year in first-line pancreatic cancer, with enrollment expected to commence in the first half of 2019.
In 2018, following the positive results in second-line metastatic pancreatic cancer, ERYTECH also evaluated other potential solid tumor indications and selected metastatic triple-negative breast cancer (TNBC) as the next indication for which to pursue clinical development of eryaspase. ERYTECH is preparing for a Phase 2 proof-of-concept clinical trial in this indication, with the first patient expected to be enrolled in the fourth quarter of 2018. ERYTECH is also evaluating development options in other pancreatic cancer settings and in additional solid tumor indications with high unmet medical need.
In order to ensure adequate supply of eryaspase for its planned clinical trials, as well as the potential commercialization of eryaspase, if approved, the Company is constructing a large-scale manufacturing facility in the United States (Princeton, New Jersey) and is also expanding its manufacturing capacity in Lyon, France. ERYTECH expects both facilities to be operational for clinical production at the expanded capacity in the first quarter of 2019.
Despite having observed favorable efficacy results and safety profile in multiple clinical trials of eryaspase in patients with ALL, ERYTECH now believes, based on recent feedback from the regulatory agencies in Europe and the United States, that significant additional investment would be required in order to seek regulatory approval of eryaspase for the treatment of ALL. In the context of the rapidly changing and increasingly competitive landscape with newly-approved treatment options for ALL, the regulatory requirements and what ERYTECH observes to be a limited market opportunity for eryaspase in ALL, ERYTECH has elected to cease further clinical development efforts in ALL and to withdraw its European MAA. The resources that will become available as a result of this strategic decision will be allocated to what ERYTECH estimates is a significantly larger unmet medical needs and market opportunity for the potential treatment of solid tumors.
ERYTECH's preclinical development efforts are not affected by this strategic decision. The next product candidate, erymethionase, methionine-g-lyase encapsulated in red blood cells, and the ERYMMUNE (immuno-therapy) research program are also targeting solid tumor indications. ERYTECH intends to initiate a Phase 1 clinical trial of erymethionase later this year, with enrollment expected to commence in the first half of 2019.
Conference Call Details
ERYTECH management will hold a conference call on Monday, June 25, 2018 at 02:30pm CET / 08:30am EDT. Gil Beyen, Chairman and CEO, Eric Soyer, CFO and COO and Iman El-Hariry, CMO will be available for a Q&A session.
The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 6590689#:
|USA/Canada: +1 833 818 6807
Belgium: +32 24003547
Spain: +34 914142503
Finland: +358 972519310
Sweden: +46 856619361
|France: +33 176748988
Switzerland: +41 445802606
Germany: +49 6922224728
United-Kingdom: +44 2031070289
Netherlands: +31 207075547
An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 6590689#.
About ERYTECH: www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated promising efficacy and safety results in various clinical trials in ALL, as well as in a Phase 2b trial in second-line pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). A large-scale manufacturing facility is under construction in New Jersey (USA).
In addition to eryaspase, ERYTECH is developing erymethionase, methionine-y-lyase encapsulated in red blood cells, to target cancer cells' amino acid metabolism and induce tumor cell starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Director Investor Relations
|+33 4 78 74 44 38
+1 917 312 5151
|+33 1 44 71 98 52
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans of eryaspase and erymethionase, including the expected timing for the commencement of clinical trials, as well as ERYTECH's business and regulatory strategy, and the anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, including in the Company's Document de Référence filed on April 24, 2018, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F filed on April 24, 2018 and amended on May 23, 2018, and future filings and reports made by the Company from time to time. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Erytech Pharma S.A. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
New YPO Global Leadership Survey Finds Young Business Leaders Overwhelmingly Believe Business is a Force For Good23.1.2019 06:01 | Pressemelding
Ninety-three percent surveyed say business should have a positive impact on society DAVOS, Switzerland, Jan. 23, 2019 (GLOBE NEWSWIRE) -- YPO, the premier global leadership organization for more than 27,000 chief executives, conducted a survey of its members in over 130 countries to get their thoughts on if the purpose of business is to have an impact on society beyond profits and wealth. YPO’s 2019 Global Leadership Survey , conducted 23 December 2018 through 4 January 2019 with more than 2,200 CEO respondents, found that a massive cultural shift about the role of business leadership is in progress as indicated by the following findings: • A large majority of respondents (74 percent) say their perspective on their role as a business leader has changed in the past five years. Employees (43 percent), colleagues (40 percent) and their children (37 percent) were cited as some of the top influencers behind this new belief. • Business leaders shared that they are much more inclined to make
Cloudian Provides Seamless Hybrid and Multi-cloud Storage Integration for Veeam Environments22.1.2019 20:05 | Pressemelding
Object Storage Platform Delivers Highly Cost-effective, Exabyte-scalable Backup, Archive and Disaster Recovery Under Single Data Management Architecture SAN MATEO, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cloudian today announced that its HyperStore object storage platform integrates seamlessly with Veeam’s newest data protection software release, Veeam Availability Suite 9.5 Update 4. This integration provides new and existing Veeam customers with highly cost-effective, limitlessly scalable storage that works across public and private cloud environments. With data playing an increasingly central role in an organization’s success, keeping it safe and readily available is more critical than ever. However, doing so has become more challenging in the face of continued rapid data growth. Veeam software is designed to provide both data protection and availability for all workloads—physical, virtual and cloud—and one of the key features in the new release is support of S3-compatible object
Brookfield Asset Management Notice of 2018 Year End Results Conference Call and Webcast22.1.2019 15:37 | Pressemelding
Date: Thursday, February 14, 2019 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): You are invited to participate in Brookfield Asset Management’s 2018 Year End Results Conference Call & Webcast on Thursday, February 14, 2019 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on February 14th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-688-9425 toll free in North America, or for overseas calls please dial 1-409-216-0815 (Conference ID: 7174879) at approximately 10:50 a.m. The Conference Call will also be Webcast live at ht
K2 Acquires Distributor K2NE, Strengthening Its Digital Process Automation Capabilities Across Europe22.1.2019 15:00 | Pressemelding
Acquisition expands the digital process automation company’s presence into new markets Bellevue, Wash., Jan. 22, 2019 (GLOBE NEWSWIRE) -- SourceCode Technology Holdings, Inc. (“K2”), the leader in low-code digital process automation, today announced the acquisition of one of its distributors, K2NE. With this acquisition, K2 establishes a direct presence in mainland Europe, increasing the direct customer footprint to 14 European countries, further investing and committing to growth across the continent. K2 customers will now see increased opportunities and offerings centered around strengthening their digital transformation. K2NE has a demonstrated history of strong business growth and success gaining market shares in Spain, Switzerland and Germany. “We are thrilled to welcome the K2NE team to the K2 family,” said Evan Ellis, K2 CEO. “As two organizations built around customer-first approaches to digital process automation, we can together leverage our common vision, expand our geograph
Altus Group Report Reveals Rapid Acceleration of PropTech Adoption and Rise of Disintermediation as Major Trends Impacting the Commercial Real Estate Industry in 201922.1.2019 15:00 | Pressemelding
Automation, use of AI and disintermediating business models having major impact on CRE industry; growing number of CRE firms are directly investing in PropTech companies TORONTO, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group”) (TSX: AIF), a leading provider of software, data solutions and independent advisory services to the global commercial real estate (“CRE”) industry, today released the latest Altus Group CRE Innovation Report. The report provides an outlook on technology trends impacting the global CRE industry and highlights the significant acceleration in adoption of property technology (“PropTech”), the effect of disintermediating technologies, as well as a growing trend of CRE firms investing directly in PropTech companies and startups themselves. According to the report, which is based on a global survey of 400 CRE executives at firms with assets under management (“AUM”) of at least US $250 million representing a total AUM of over US $2 trillion, driving
ATTO Technology is Now Certified DataCore Ready™ and will Showcase at the DataCore Partner Conference in Frankfurt, Germany22.1.2019 14:47 | Pressemelding
AMHERST, N.Y., Jan. 22, 2019 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for over 30 years, is proud to announce ATTO Celerity™ Gen 6 32Gb and 16Gb Fibre Channel host bus adapters (HBAs) are certified DataCore Ready™. In addition, as a member of the DataCore Ready Partner Program, ATTO will highlight its certified connectivity options for software-defined storage and data management solutions at the DataCore Partner Conference January 22-23 in Frankfurt, Germany. “We are excited to certify the ATTO Celerity HBAs as DataCore Ready as they will help IT departments achieve the flexibility and freedom that software-defined storage solutions offer, while providing the network performance and reliability that mission-critical applications need,” said Gerardo Dada, CMO of DataCore Software. “We look forward to seeing the products in action at our annual partner conference.” A